以色列Pluristem Therapeutics Inc
luristem Therapeutics, Inc.从事间质干细胞的生产技术的研究和开发，以及细胞疗法的产品的商品化。 该公司正开发一个平台，这样设计是为了创建一个功能干细胞的生产系统，可以治疗重症血液，心血管疾病，自身免疫性和其它疾病。 它开发了PluriX Bioreactor系统，该系统的设计是一个系统的基质干细胞的文化和衬底上，创建一个人工生理环境下，间质干细胞可以生长和繁殖以外的人体无任何使用外源性生物制品或生物克隆。 该公司成立于2001年，前身是AI Software, Inc.，在2003年公司改名为Pluristem Life Systems, Inc.，后来在2007年11月又改名为Pluristem Therapeutics, Inc.，公司位于以色列的Haifa。

Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products derived from human placenta, a non-controversial, non-embryonic, adult stem cell source. The (PLacental eXpanded) cell products are stored off-the-shelf, ready-to-use, and require no histocompatibility matching.

These placental adherent stromal cells (ASCs) are expanded in the Company's proprietary PluriXTM 3D bioreactor system, which provides a 3D microenvironment that enables large-scale growth of these cells without the need for supplemental growth factors or other exogenous materials. PLX cells are immune privileged, possess immunomodulatory properties, and are expanded in vitro without showing signs of phenotypic or karyotypic changes. Pluristem believes that the PLX cells?mechanism of action may be related to the secretion of cytokines and/or other potent immune modulators.

Pluristem's first product, PLX-PAD (for the treatment of Peripheral Artery Disease), received from the Food and Drug Administration (FDA) and the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, clearance to begin a 揊irst-In-Human?placental-derived mesenchymal-like stromal cell clinical trial.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.